These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://shaunagyvq403132.blog-mall.com/39817518/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide